News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
0
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2
|
|
Created
|
11/06/22
|
Type
|
Free
|
| Moderators | |||
We are focused on developing medical products and regimens that address addiction.
Click to learn more
Nirvana was founded with the intent to develop novel therapeutic products derived from psychedelics.
There is a body of research that leads to the conclusion that psychedelic based medicines can offer new approaches to pain management as well as treatment for ailments such addiction, anxiety and depression.
We believe that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction.
Opioid addiction has become a major health crisis that has a massive cost to our society. Existing approaches to breaking addiction have not been successful.
A successful approach to break addiction and offering non-addictive pain management products will offer great benefit to society and a successful drug development project for the Company.
The Company’s goal is twofold; to develop psilocybin derived medicines that can break human addictions to Opioids, and non-addictive pain relief that can replace the need for Opioid medicines.
For many years, the pharmaceutical Industry has promoted the use of highly addictive pain medications to millions of patients. While these medications have been effective for pain relief, the highly addictive nature of the medications has created a problem with no practical solution. The result has been millions of people becoming addicted to opioid medications, some who have turned to street versions of these drugs to manage their pain.
The actions of these pharmaceutical companies have a devastating impact on families and communities. Current solutions proposing free or lower cost opioids is not a solution, society needs practical methods to break addiction, prevent relapse and replace addictive pain management therapies with non-addictive therapies.
The US Council of Economic Advisors estimate the cost to the US economy at more than $500 billion annually, this equates to -almost 4% of GDP. In 2017, more that 70,000 Americans died of drug overdose, with around two-thirds of those deaths linked to opioids. The impact can be measured financially, with massive health care and insurance costs as well as the significant costs of law enforcement. It has been estimated that it will require a large investment, as much as $100 billion, to fully address the crisis.
The Company’s Scientific team is taking theories developed by researchers in the 60’s and 70’s and applying modern approaches to developing novel psychedelics-based formulations. Company researchers believe that its Psilocibyn formulation may also be effective at preventing relapse. Nirvana has begun pre-clinical trials into the efficacy of Psilocybin based formulations as a therapeutic tool to break addiction to opioids.
Clinical Studies are led by Dr. Massimo Nabissi, of the University of Camerino (Italy), with the support of Dr. Sazzad Hossain. Ongoing pre-clinical trials to validate that the Psilocybin based formulation is effective at breaking addiction is the first step. This will be followed with further development of psychedelics-based formulations that may eventually create a range of potential products based on results of these trials.
UniCam has proposed additional studies for use of the formulations for Anxiety and Depression which can be undertaken in further phases of the project. Further trials have been planned for a range of formulations under development.
The Company has selected two products for its first phase of development.
Click to learn more
Development of similar products in a transdermal patch format will also be pursued. These prototype products will enter the next phase of development in the third quarter of 2022.
Any number of therapeutic medicines and products can be created from our formulations. As many of our formulations will be dealing with the treatment or management of opioid addiction or dependency, we have prioritized the development of non-abusive delivery systems. This will be an advance over conventional delivery systems such as tablets or inhalants that can be abused by over consumption and overdosing.
Our scientific team has been successful at developing various formulations to deter the possibility of abuse by developing and using various methods of ‘compound coupling’.
What this entails is attaching a natural backbone to the active compounds chemical structure to form a ‘complex’. This can be done using safely approved amino acids and metals salts. The medicines produced via this method would be rendered inactive if consumed in any manner other than orally because the formulation must first pass through the gut in order to break the active compound free from its coupled backbone. IV use or insufflation would not be effective at releasing the active thus rendering it safe.
The company has purchased a portfolio of Intellectual Property from researchers with vast experience in the psychedelics space.
Click to learn more
Also, since psilocybin potency diminishes upon exposure to water and UV light, our novel carriers and encapsulation process utilize both anhydrous carrier liquids and UVA&B resistant gelatins for our precisely dosed Soft gel capsules.
As legalized medicinal use of psilocin, psilocybin and other naturally derived tryptamines is a new frontier, this leaves open a great deal of opportunity to seize the market on new FDA approved formulations.
In addition to novel formulation development, there is also the opportunity for IP development for the mechanized manufacturing of these new medicines that incorporate our Licensed delivery systems and mechanisms.
The Company’s extraction process development includes large scale extraction, isolation and purification of psilocybin and other active tryptamines from various sources of refined biomass material consisting of both grown fungi and enzymatic de novo crude. Since psilocybin and psilocin are susceptible to rapid degradation when exposed to heat, water and oxygen, we had to develop a viable and cost-effective method of extraction in anaerobic and anhydrous conditions.
The process for synthesizing materials such as psilocybin has been around for many years. In fact, our team members were involved with developing many of the routes steps and the streamlining of the synthesis process.
The reason that no one has come forward with a viable method of extracting active tryptamines from biomass material like mushrooms or mycelium is because it is not an easy process to streamline and the yields have been poor.
Nirvana has acquired an exclusive license to the extraction and distillation technology for the Psychedelics market. The Company has purchased its first PureAI machine that will be in the Vancouver Lab facility. The Pure AI is a high vacuum fractional distillation system that should allow us to achieve separations of non-tryptamine compounds at a lower temperature than conventional fractional distillation systems.
The pure AI system will be used exclusively to isolate secondary and tertiary compounds that will be used for further research and study and to formulate new medicines. It is this level of research that will separate our work from companies that are simply trying to reach the finish line of API grade extraction of biomass and biomaterial. These isolated compounds will be studied in formulations clinically and our products formulated with these compounds will set us apart in the market.
The Pure AI produces compounds that are pure in nature since the technology has the ability of separating pristine compounds from complex mixtures due to incorporating the use of vapor temperature within a static multiple theoretical plate system.
As only a single compound or component boils at a specific temperature under a high vacuum system, the machine uses this law of physics to separate out pure compounds by both molecular weight and the law of entropy and thermodynamics.
Dr. Gaur and Dr. Barse of the International Centre for Genetic Engineering and Biotechnology of New Delhi, India has been contracted will undertake a research project on a novel process developed by the Company’s CSO to assess the ability to produce psilocybin materials at scale.
The project is focussing on strain engineering to achieve a cost- competitive large-scale fermentative production of psilocybin with a purity of >98% in kilogram batch quantities for use as an API”
For the next stage we are developing a means of adapting this extraction method for large scale pharmaceutical GMP production of clinical grade psilocybin.
The Company has acquired an exclusive license to a proprietary extraction technology that will support these developments.
The company has secured a location in Vancouver to conduct research that is suitable for this development. The company has received a Section 56 Exemption (research license) from Health Canada. The team has extensive experience planning and building similar facilities.
The facility will be built out to a level 9 Security standard, the 2,500 square foot lab space will facilitate all foreseeable activities as well allowing for scaling and expansion. These activities will include research of novel compounds, extraction and purification methods. The Company has applied to Health Canada for Dealer’s License that will allow for movement of materials between licensees.
Nirvana is planning on growing several genera and species of fungi (including rare and hybrid varieties) with a high standard of quality and batch consistency.
Click to learn moreUsing fungi to extract the active tryptamines from the biomass to yield psilocybin and psilocin in the form of pure crystalline isolate, salts, tinctures and high bioavailable water-soluble liquids and dry powders. Nirvana plans to sell these products to other researchers under a Dealer’s License from Health Canada.
The extraction of psilocybin and other structurally similar substituted tryptamines from fungi followed by their conversion to the metabolic prodrug 4-POpsilocin. This process is a novel method to yield a new psychoactive substituted tryptamine that has a highly desirable effect. The onset is fairly rapid and the duration is roughly 4 hours.
This novel compound will be ideal for use in a clinical setting due to its short duration and the lack of any apparent body load that’s often associated with psilocybin. We are currently in the finalization phase of the patent process and acquiring this compound for exclusive use in the clinical pharmaceutical market.
Nirvana is also in the process of creating a fully synthetic route to yield psilocybin and psilocin from 4-hydroxytryptophan in large batch quantities. This synthetic psilocybin will be a standardized USP grade pharmaceutical.
Ibogaine is a naturally occurring alkaloid that has been reported to decrease various adverse phenotypes associated with exposure to drugs of abuse and alcohol in human and rodent models. We believe that this compound could be valuable as a clinical medication when used cautiously. We have developed an exclusive multi-phase process to extract ibogaine alkaloids from the root bark of the tabernanthe iboga shrub. This extraction process yields both a broad spectrum total alkaloid freebase powder and a pure hydrochloride salt. We are currently in the process of developing a cost effective batch scale synthesis of noribogaine and its 13-hydroxy variant. Noribogaine (12-hydroxyibogamine) is a metabolite of ibogaine.
In addition to novel formulation development, there is also the opportunity for IP development for the mechanized manufacturing of these new medicines that incorporate our Licensed delivery systems and mechanisms.
We are focused on developing medical products and regimens that address addiction.
Learn MoreAnnie Storey
Edward Lupton
Chris Hoffmeister
Mark Marissen
Bruce Clark
Mr. Clark leads the Nirvana team, seeking new solutions to one of our society’s most confounding issues. He sees great potential in the opportunity to development of new approaches to a complex problem which is both a public health and economic issue for our communities. Mr. Clark is a proven innovator who brings 30 years management experience across a variety of industries, including energy, food and beverage manufacturing and life science. He possesses broad experience in product development, manufacturing and product distribution and a clear understanding of the regulatory process. He has a deep understanding of the public policy issues at play and the importance of collaboration with all levels of government and health professionals through the development process.
Ms. Hang has over 20 years of finance, accounting, and management experience in a variety of industries, including energy, mining, and health science.
In the past 12 years Ms. Hang has acted as an advisor, officer and/or director for various public and private companies, which span across Canadian based companies to foreign controlled entities.
From 1999 to 2009, Ms. Hang worked in professional accounting firms and held senior positions in tax and audit practices.
Having served over 40 public and private companies, which span across Canadian based companies to foreign controlled entities, she has gained in- depth knowledge of financial and regulatory affairs.
Her experience in dealing with people from different cultures and disciplines has solidified her ability to understand the needs of stakeholders and communicate complex ideas.
Ms. Hang is a Member of the Chartered Professional Accountants of Canada and British Columbia and holds a Bachelor of Accounting Science from University of Calgary.
Dr. Hossain is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company.
Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada.
Dr Hossain is a drug discovery leader over 15 years of biotech/pharmaceutical experience with small molecule & biologics in multiple disease indications.
He has experience in accelerated drug discovery and commercialization process with combined experience in preclinical in vivo pharmacology, DMPK, safety & toxicology.
He has led teams in the strategic design of new natural health products and generated hundreds of millions of dollars in revenue by leading development of multiple successful compounds.
Dr Hossain holds a PhD in Biology and was a post doctoral Fellow at the Centre for Molecular Medicines and Therapeutics at the University of BC
Robert August is an academically trained medicinal chemist with a focus on ergolines, phenethylamines and tryptamines.
Robert began his academic career at Loyola University in Baltimore, Maryland. During his undergraduate years, Robert worked as an analytical chemist for Martel Laboratories where he received his state analytical certifications for ICP, GC/MS and LC/MS operations. While pursuing a post graduate degree in medicinal chemistry at Johns Hopkins University, Robert turned his focus toward the synthesis of psychoactive and psychedelic compounds, namely ergolines such as LSD and phenethylamines like MDMA and 2CB.
It is during this time that Robert began to work as a research chemist and, eventually, began to actively pursue working partnerships with other chemists who were researching psychedelic compounds like Dr. David E. Nichols and Nick Sand with whom Robert worked with briefly in Vancouver, B.C.
After earning a reputation as a skilled chemist, Robert was invited to work alongside Ben Alkire (Purdue University) in Lafayette, Indiana where he went on to cofound Berkeley-Clearlight Research Group.
While forming BCRG, Robert was given unlimited access to the D.E. Nichols Archive at Purdue University and the vast array of synthesis notes created by Dr. Oberlender during his time as a chemist for the Nichols team.
In the years that followed, Robert synthesized numerous novel compounds and research chemicals and became the first person to synthesize 3,4-MDMA Monohydrate HCl as a crystalline solid and as a beta ketone. Robert is a highly respected member of the psychedelic community and an advocate for ending prohibition.
Mr. McCune is a seasoned entrepreneur and innovator in the extraction space.
Since 2013, he has applied his passion for science to developing novel processes for producing API’s for Cannabis industry. He has built a specialty for at-scale extraction of a wide variety of materials.
He led the development of a leading-edge distillation system that offers significant operational advantages and automation. He has overseen the development, trials and contract manufacture of this system.
Michael is recognized as a lead leader in these technologies and has co-authored several Patents. He maintains a global network and has presented at numerous conferences on the topics of Extraction and Cannabis Technologies.
Download the investor deck.
CLICK TO DOWNLOADEmail us:
investor@nirvanalifescience.com
Nirvana Life Sciences
6th Floor. 905 West Pender St.
Vancouver BC
V6C1L6
AI
